Tinnitus
Drug research and approvals for tinnitus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 42 studies of tinnitus are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.
- Recruiting worldwide: 42
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting now
Newest start dates first, of 42 recruiting on ClinicalTrials.gov ↗- A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)NCT07777549 · Phase 2 · Tortugas Neuroscience, Inc. · starts Oct 14, 2026
- Deep Repetitive Transcranial Magnetic Stimulation in the Treatment of TinnitusNCT07885176 · Not applicable · University of Regensburg · starts Sep 19, 2026
- Non-Invasive Neurofeedback Training to Alleviate Tinnitus DistressNCT07788638 · Not applicable · University of Illinois at Urbana-Champaign · starts Aug 12, 2026
- Transitional Intervention for Hyperacusis in AutismNCT07798297 · Not applicable · University of Central Florida · starts Aug 1, 2026
- Diet Restiction in Subjects With Behcet Disease and Complaint of TinnitusNCT07702149 · Not applicable · Cairo University · starts Jun 4, 2026
- FR-taVNS Tinnitus TriaNCT07711639 · Not applicable · Tzu Chi University · starts Apr 28, 2026
- VivaStent Feasibility StudyNCT07515781 · Not applicable · V-Flow 21 · starts Apr 8, 2026
- BosSTENT ImpLant to trEat debilitatiNg Pulse-synchronous TinnitusNCT07070089 · Not applicable · Sonorous NV, Inc · starts Feb 1, 2026
- Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal TinnitusNCT07393880 · Not applicable · University of Dublin, Trinity College · starts Jan 30, 2026
- Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term AcetazolamideNCT06945848 · Not applicable · University Hospital, Montpellier · starts Jan 5, 2026
Drug pipeline
3 in phase 3, 12 in phase 2, 4 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Esketamine
- Phase 3 Glutamate [NMDA] receptor negative allosteric modulator
- Neramexane
- Phase 3 Neuronal acetylcholine receptor; alpha9/alpha10 antagonist
- Oxytocin
- Phase 3 Oxytocin receptor agonist
- Gabapentin
- Phase 2 Voltage-gated calcium channel modulator
- Gacyclidine
- Phase 2
- Etanercept
- Phase 2 TNF-alpha inhibitor
- Paroxetine
- Phase 2 Serotonin transporter inhibitor
- Botulinum toxin type a
- Phase 2 Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
- Brexanolone
- Phase 2 GABA-A receptor; anion channel positive allosteric modulator
- Vardenafil
- Phase 2 Phosphodiesterase 5A inhibitor
- Ketamine
- Phase 2 Glutamate [NMDA] receptor negative allosteric modulator
- Vestipitant
- Phase 2 Neurokinin 1 receptor antagonist
- Selurampanel
- Phase 2 Glutamate receptor ionotropic AMPA antagonist
- Sulodexide
- Phase 2
- Zinc ion
- Phase 2
- Modafinil
- Phase 1 Dopamine transporter inhibitor
- Acamprosate
- Phase 1 Glutamate [NMDA] receptor antagonist
- Cannabinol
- Phase 1
- Lidocaine
- Early phase 1 Sodium channel alpha subunit blocker
How its trials ended
344 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 67 whose ending is known, 37% met their primary endpoint, 13% missed it and 49% stopped early.
- Completed, result not reported15946%
- Ongoing6619%
- Status unknown5215%
- Met its primary endpoint257%
- Stopped: other or unclear247%
- Missed its primary endpoint93%
- Stopped: lack of efficacy31%
- Stopped: enrollment or feasibility21%
- Stopped: sponsor or business decision21%
- Stopped: funding21%
Trials authorized in Canada
Newest first; search them all in Canada trials| Feb 27, 2014 | Am-101 in the post-acute treatment of peripheral tinnitus 1 (AMPACT1) - an open-label extension to the TACTT2 studyEsketamine (AM-101) | Auris Medical Inc | Closed |
| Dec 23, 2013 | Efficacy and safety of AM-101 in the treatment of acute peripheral tinnitus 2 (TACTT2)Esketamine | Auris Medical Inc | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA